Jazz Pharmaceuticals Income Statement
JAZZ / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Jazz Pharmaceuticals reported $4.3B in revenue and $356M in net loss for FY2025. Revenue has grown at a 21.7% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B | $2.4B | $1.6B | $1.5B | $376.1M | $1.2B | $1.3B | $586.0M | $872.4M | $586.0M | $272.3M |
| Gross Profit | - | - | - | - | - | - | $469.8M | $406.9M | $348.6M | $310.5M | $278.7M | $214.1M | $167.4M | - | - |
| SG&A Expense | $1.8B | $1.4B | $1.3B | $1.4B | $1.5B | $854.2M | $544.2M | $502.9M | $544.2M | $406.1M | $449.1M | $223.9M | $304.3M | $223.9M | $108.9M |
| R&D Expense | $782.7M | $884.0M | $849.7M | $590.5M | $505.7M | $335.4M | $198.4M | $162.3M | $198.4M | $85.2M | $135.3M | $20.5M | $41.6M | $20.5M | $14.1M |
| Operating Income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M | $378.1M | $528.8M | $591.7M | $528.8M | $195.6M | $508.2M | $197.8M | $340.3M | $197.8M | $127.8M |
| Interest Expense | - | - | $32.8M | $32.8M | $89.9M | $87.6M | $37.8M | $27.5M | $37.8M | - | $26.5M | - | - | - | $1.7M |
| Income Tax | -$272.4M | -$91.4M | -$119.9M | -$158.6M | $216.1M | $33.5M | -$47.7M | $135.2M | -$47.7M | $94.2M | $106.4M | -$83.8M | $91.6M | -$83.8M | $0 |
| Net Income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M | $238.6M | $487.8M | $396.8M | $487.8M | $58.4M | $329.5M | $288.6M | $216.3M | $288.6M | $125.0M |
| EPS (Basic) | -$5.84 | $9.06 | $6.55 | -$3.58 | -$5.52 | $4.28 | $8.13 | $6.56 | $5.38 | $0.98 | $3.71 | $5.09 | $3.01 | $5.09 | -$0.23 |
| EPS (Diluted) | -$5.84 | $8.65 | $6.10 | -$3.58 | -$5.52 | $4.22 | $7.96 | $6.41 | $5.23 | $0.93 | $3.51 | $4.79 | $2.67 | $4.79 | -$0.23 |
| Shares Outstanding | 61.0M | 60.6M | 62.3M | 63.2M | 61.6M | 56.2M | 57.7M | 58.9M | 59.8M | 61.3M | 60.6M | 57.9M | 58.0M | 58.0M | 40.0M |
| Gross Margin | - | - | - | - | - | - | 29.0% | 27.4% | 92.7% | 26.5% | 21.0% | 36.5% | 19.2% | - | - |
| Operating Margin | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% | 32.7% | 39.8% | 140.6% | 16.7% | 38.4% | 33.8% | 39.0% | 33.8% | 46.9% |
| Profit Margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | 10.1% | 30.1% | 26.7% | 129.7% | 5.0% | 24.9% | 49.3% | 24.8% | 49.3% | 45.9% |